Ginkgo Bioworks Holdings, Inc. DNA
Our mission is to make biology easier to engineer. That has never changed. Every choice we've made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
1.Biology is programmable. All living things run on the same DNA code.
2.Biology matters. The ability to engineer biology has had and will have a profound impact on how we develop new medicines and vaccines, grow our food, and manufacture many of the things we use every day.
3.Biology is hard. Today, it is still too difficult and too costly to engineer biology, preventing critical innovations from reaching the market.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Cell Engineering
- Biosecurity - Service
- Other
| Segment | FY2025 | FY2024 |
|---|---|---|
| Cell Engineering | $132.7M | $174.0M |
| Biosecurity - Service | $37.4M | $53.1M |
| Other | $0 | $0 |
As the company reported it, from the “Segment Information - Schedule of Segment Reporting Information, by Segment (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M | — |
| R&D | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B | $159.8M | $96.3M | — |
| SG&A | $183.3M | $246.2M | $385.0M | $1.43B | $863.0M | $38.3M | $29.5M | — |
| Total operating expenses | $485.4M | $786.8M | $1.12B | $2.69B | $2.14B | $213.7M | $125.8M | — |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.21B | -$1.83B | -$137.0M | -$71.6M | — |
| Interest expense | $0 | $94.0K | $93.0K | $106.0K | $2.4M | $2.4M | $2.4M | — |
| Pre-tax income | -$313.6M | -$547.5M | -$892.9M | -$2.12B | -$1.84B | -$124.8M | -$119.8M | — |
| Income tax | $837.0K | $479.0K | $71.0K | $15.0M | $1.5M | $1.9M | $22.0K | — |
| Net income | -$313.0K | -$547.0K | -$893.0K | -$2.1M | -$1.8M | -$126.6M | -$119.3M | — |
| EPS, basic | -5.64 | -10.54 | -18.37 | -50.15 | -1.35 | -0.10 | -0.10 | — |
| EPS, diluted | -5.64 | -10.54 | -18.37 | -50.20 | -1.39 | -0.10 | -0.10 | — |
| Shares, diluted (wtd. avg.) | 55.5M | 51.9M | 48.6M | 42.0M | 1.36B | 1.27B | 1.15B | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $167.2M | $561.6M | $944.1M | $1.32B | $1.55B | $380.8M | $495.3M | $207.4M |
| Short-term investments | $255.4M | $0 | — | — | — | — | — | — |
| Receivables | $24.0M | $21.9M | $17.2M | $80.9M | $131.5M | $16.7M | — | — |
| Inventory | — | — | $46.0K | $4.4M | $3.4M | $2.7M | — | — |
| Total current assets | $471.8M | $602.7M | $1.00B | $1.45B | $1.72B | $426.5M | — | — |
| Property, plant and equipment | $167.8M | $203.7M | $188.2M | $314.8M | $145.8M | $121.4M | — | — |
| Goodwill | — | $0 | $49.2M | $60.2M | $21.3M | $1.9M | $1.9M | — |
| Other intangibles | $56.9M | $72.5M | $82.7M | $111.0M | $21.6M | $3.3M | — | — |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B | $675.2M | — | — |
| Accounts payable | $10.6M | $14.2M | $9.3M | $10.5M | $8.2M | $13.9M | — | — |
| Total current liabilities | $96.0M | $107.3M | $163.9M | $173.0M | $134.8M | $73.2M | — | — |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803.0M | $503.6M | $205.1M | — | — |
| Retained earnings | -$6.15B | -$5.84B | -$5.29B | -$4.40B | -$2.30B | -$467.9M | — | — |
| Total equity | $508.6M | $716.1M | $1.10B | $1.74B | $1.57B | $470.1M | $501.9M | $213.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M | -$135.8M | -$44.7M | — |
| Depreciation and amortisation | $40.3M | $45.0M | $54.8M | $36.9M | $26.9M | $12.6M | $9.6M | — |
| Stock-based compensation | $81.5M | $112.3M | $229.9M | $1.93B | $1.61B | $476.0K | $771.0K | — |
| Capital expenditure | $7.7M | $62.5M | $40.8M | $52.3M | $56.5M | $57.8M | $22.2M | — |
| Investing cash flow | -$240.3M | -$62.2M | -$80.7M | -$67.4M | -$73.3M | -$67.1M | -$74.6M | — |
| Financing cash flow | $17.8M | -$1.7M | -$3.2M | $95.3M | $1.53B | $90.3M | $410.4M | — |
| Buybacks | — | — | — | — | — | — | $408.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028377.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $54.2M | $76.7M | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$119.3M | -$126.6M | -$1.8M | -$2.1M | -$893.0K | -$547.0K | -$313.0K |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |